首页> 外文期刊>The American Journal of Tropical Medicine and Hygiene >The Interruption of Transmission of Human Onchocerciasis by an Annual Mass Drug Administration Program in Plateau and Nasarawa States, Nigeria
【24h】

The Interruption of Transmission of Human Onchocerciasis by an Annual Mass Drug Administration Program in Plateau and Nasarawa States, Nigeria

机译:尼日利亚高原和纳斯加瓦州的年大众药物管理计划中断人类持续的人类传播

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Plateau and Nasarawa states in central Nigeria were endemic for onchocerciasis. The rural populations of these two states received annual ivermectin mass drug administration (MDA) for a period of 8-26 years (1992-2017). Ivermectin combined with albendazole was given for 8-13 of these years for lymphatic filariasis (LF); the LF MDA program successfully concluded in 2012, but ivermectin MDA continued in areas known to have a baseline meso-/hyperendemic onchocerciasis. In 2017, serological and entomological assessments were undertaken to determine if MDA for onchocerciasis could be stopped in accordance with the current WHO guidelines. Surveys were conducted in 39 sites that included testing 5- to < 10-year-old resident children by using ELISA for OV16 IgG4 antibodies, and Onchocerca volvulus O150 pooled polymerase chain reaction (PCR) testing of Simulium damnosum s.l. vector heads. Only two of 6,262 children were OV16 positive, and none of 19,056 vector heads were positive for parasite DNA. Therefore, both states were able to meet WHO stop-MDA thresholds of an infection rate in children of < 0.1% and a rate of infective blackflies of <1/2,000, with 95% statistical confidence. Transmission of onchocerciasis was declared interrupted in Plateau and Nasarawa states by the Federal Ministry of Health, and 2.2 million ivermectin treatments/year were stopped in 2018. Post-treatment Surveillance was launched focusing on entomological monitoring on borders with neighboring onchocerciasis-endemic states. An apparent positive impact of the LF MDA program on eliminating hypo-endemic onchocerciasis was observed. This is the first stop-MDA decision for onchocerciasis in Nigeria and the largest single stop-MDA decision for onchocerciasis yet reported. This achievement, along with the process used in adapting and implementing the 2016 WHO stop-MDA guidelines, will be important as a potential model for decision makers and national onchocerciasis elimination committees in other African countries that are charged with advancing their programs.
机译:尼日利亚中部的高原和纳斯加拉州国家为onchocerciasis流行。这两种州的农村群体每年伊维菌素大规模药物管理局(MDA)为期8-26岁(1992-2017)。伊维菌素联合阿尔贝扎唑,对淋巴丝体(LF)淋巴丝体(LF)中的8-13岁; LF MDA计划于2012年成功结束,但IverMectin MDA在已知的地区继续进行基线中间血糖癌症。 2017年,进行了血清学和昆虫学评估,以确定是否可以按照当前准则停止对onchocerciasis的MDA。通过使用ELISA用于OV16 IgG4抗体的ELISA和onchocerca Volvulus O150合并聚合酶链反应(PCR)试验,在39位点进行调查,包括使用ELISA对ov16 IgG4抗体进行测试,并进行SimnOnosum S.L的汇集聚合酶链反应(PCR)测试。矢量头。 6,262名儿童中只有两个是OV16阳性,19,056个载体头部没有寄生虫DNA阳性。因此,两国都能够满足谁,儿童感染率的阈值<0.1%,感染率为<1 / 2,000的感染率,具有95%的统计信心。在联邦卫生部的高原和纳萨拉瓦国家宣布宣布的onchocerciaSis的传播,2018年停止了220万伊维菌素治疗/年。启动了治疗后监测,重点是关于与邻近的邻近的邻近的邻近的邻近的昆虫学监测。观察到LF MDA方案对消除吞噬特有的onchocerciasis的表观积极影响。这是尼日利亚onChocerciasis的第一个停止MDA决定,以及尚未报道的onchocerciasis的最大单秒钟决定。这一成就以及用于调整和实施2016年停止MDA指南的过程,作为决策者和国家onchocerciaSis在其他非洲国家的消除委员会的潜在模型,这是一个被指控推进其计划的潜在模式。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号